These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 15809366

  • 1. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
    Stewart RA, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, West MJ, Colquhoun DM, Tonkin AM, Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Investigators.
    Circulation; 2005 Apr 12; 111(14):1756-62. PubMed ID: 15809366
    [Abstract] [Full Text] [Related]

  • 2. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators.
    Am Heart J; 2003 Apr 12; 145(4):643-51. PubMed ID: 12679760
    [Abstract] [Full Text] [Related]

  • 3. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.
    Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH, Howard BV, Assaf AR, Prentice R, Women's Health Initiative Research Group.
    Arch Intern Med; 2005 Mar 14; 165(5):500-8. PubMed ID: 15767524
    [Abstract] [Full Text] [Related]

  • 4. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):914-20. PubMed ID: 18772061
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study.
    Haim M, Boyko V, Goldbourt U, Battler A, Behar S.
    Arch Intern Med; 2004 Feb 23; 164(4):433-9. PubMed ID: 14980995
    [Abstract] [Full Text] [Related]

  • 6. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB.
    Fortschr Med; 1996 Mar 20; 114(8):91-8. PubMed ID: 8647574
    [Abstract] [Full Text] [Related]

  • 7. Pravastatin therapy and the risk of stroke.
    White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, Colquhoun DM, Glasziou P, MacMahon S, Kirby AC, West MJ, Tonkin AM.
    N Engl J Med; 2000 Aug 03; 343(5):317-26. PubMed ID: 10922421
    [Abstract] [Full Text] [Related]

  • 8. Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis.
    Ovbiagele B, Lynn MJ, Saver JL, Chimowitz MI, WASID Study Group.
    Cerebrovasc Dis; 2007 Aug 03; 24(2-3):283-8. PubMed ID: 17646693
    [Abstract] [Full Text] [Related]

  • 9. White blood cell count and the incidence of ischemic stroke in coronary heart disease patients.
    Koren-Morag N, Tanne D, Goldbourt U.
    Am J Med; 2005 Sep 03; 118(9):1004-9. PubMed ID: 16164887
    [Abstract] [Full Text] [Related]

  • 10. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
    Sabatine MS, Ploughman L, Simonsen KL, Iakoubova OA, Kirchgessner TG, Ranade K, Tsuchihashi Z, Zerba KE, Long DU, Tong CH, Packard CJ, Pfeffer MA, Devlin JJ, Shepherd J, Campos H, Sacks FM, Braunwald E.
    Arterioscler Thromb Vasc Biol; 2008 Mar 03; 28(3):562-7. PubMed ID: 18174457
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E, PEACE Investigators.
    Circulation; 2007 Mar 27; 115(12):1528-36. PubMed ID: 17372173
    [Abstract] [Full Text] [Related]

  • 12. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group.
    N Engl J Med; 2007 Oct 11; 357(15):1477-86. PubMed ID: 17928595
    [Abstract] [Full Text] [Related]

  • 14. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J, PROSPER Study Group.
    Circulation; 2007 Feb 27; 115(8):981-9. PubMed ID: 17283264
    [Abstract] [Full Text] [Related]

  • 15. The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction.
    Grzybowski M, Welch RD, Parsons L, Ndumele CE, Chen E, Zalenski R, Barron HV.
    Acad Emerg Med; 2004 Oct 27; 11(10):1049-60. PubMed ID: 15466147
    [Abstract] [Full Text] [Related]

  • 16. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, Shepherd J.
    Eur Heart J; 2002 Feb 27; 23(3):207-15. PubMed ID: 11792135
    [Abstract] [Full Text] [Related]

  • 17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 27; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 18. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery.
    Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B.
    J Cardiothorac Vasc Anesth; 2006 Feb 27; 20(1):51-6. PubMed ID: 16458214
    [Abstract] [Full Text] [Related]

  • 19. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, ALLHAT Collaborative Research Group.
    J Am Coll Cardiol; 2009 Nov 24; 54(22):2023-31. PubMed ID: 19926008
    [Abstract] [Full Text] [Related]

  • 20. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
    White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg S, LIPID Study Investigators.
    J Am Coll Cardiol; 2014 Feb 04; 63(4):345-54. PubMed ID: 24140630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.